会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 1. 发明授权
    • Pyrazine derivatives
    • 吡嗪衍生物
    • US07273868B2
    • 2007-09-25
    • US10699804
    • 2003-11-04
    • Koichiro YamadaKenji MatsukiKenji OmoriKohei Kikkawa
    • Koichiro YamadaKenji MatsukiKenji OmoriKohei Kikkawa
    • C07D401/12C07D403/12A61K31/4025A61K31/4965
    • C07D239/48C07D401/12C07D401/14C07D403/04C07D403/14C07D413/04C07D413/14C07D417/14C07D471/04C07D487/04C07D513/04C07F9/6512C07F9/65583
    • 1. A cyclic compound of the formula (I) or a pharmacologically acceptable salt thereof, wherein X is ═CH— or ═N—, Y is —NH—, —NR4—, —S—, —O—, —CH═N—, —N═CH—, —N═N—, —CH═CH—, etc., R1 is a lower alkoxy group, an amino group, a heterocyclic ring containing N atom(s), or a hydroxy group substituted by a heterocyclic ring containing N atom(s) (each of which is optionally substituted), R2 is a lower alkylamino group which is optionally substituted by an aryl group, a lower alkoxy group which is optionally substituted by an aryl group, a lower alkoxy group substituted by an aromatic heterocyclic ring containing N atom(s), R3 is an aryl group, a heterocyclic ring containing N atom(s), a lower alkyl group, a lower alkoxy group, a cyclo lower alkoxy group, a hydroxy group substituted by a heterocyclic ring containing N atom(s), or an amino group (each of which is optionally substituted), and R3 and a substituent in Y may be combined to form a lactone ring. The compound of the present invention has excellent selective PDE V inhibitory activity and therefore, is useful as a therapeutic or prophylactic drug for treating various diseases due to functional disorders on cGMP-signaling.
    • 1.式(I)的环状化合物或其药理学上可接受的盐,其中X是-CH-或-N-,Y是-NH-,-NR 4 - , - S- ,-O - , - CH-N - , - N-CH - , - N - , - CH-CH-等,R 1是低级烷氧基,氨基, 含有N原子的杂环或被含有N原子(各自任选被取代的)的杂环取代的羟基,R 2是任选地是低级烷基氨基 被芳基取代,任选被芳基取代的低级烷氧基,被含有N原子的芳族杂环取代的低级烷氧基,R 3是芳基, 含有N原子,低级烷基,低级烷氧基,环低级烷氧基,被含有N原子的杂环取代的羟基或氨基的杂环(各自为 任选取代的)和R 3和Y中的取代基可以组合形成 内酯环。 本发明的化合物具有优异的选择性PDE V抑制活性,因此可用作治疗或预防药物,用于治疗由于cGMP信号传导的功能紊乱引起的各种疾病。
    • 2. 发明授权
    • Pyrimidine compounds
    • 嘧啶化合物
    • US07220736B2
    • 2007-05-22
    • US10258545
    • 2001-03-15
    • Koichiro YamadaKenji MatsukiKenji OmoriKohei Kikkawa
    • Koichiro YamadaKenji MatsukiKenji OmoriKohei Kikkawa
    • C07D239/42C07D401/12A61K31/505C07D471/04
    • C07D239/48C07D401/12C07D401/14C07D403/04C07D403/14C07D413/04C07D413/14C07D417/14C07D471/04C07D487/04C07D513/04C07F9/6512C07F9/65583
    • A cyclic compound of the formula (I) or a pharmacologically acceptable salt thereof, wherein X is ═CH— or ═N—, Y is —NH—, —NR4—, —S—, —O—, —CH═N—, —N═CH—, —N═N—, —CH═CH—, etc., R1 is a lower alkoxy group, an amino group, a heterocyclic ring containing N atom(s), or a hydroxy group substituted by a heterocyclic ring containing N atom(s) (each of which is optionally substituted), R2 is a lower alkylamino group which is optionally substituted by an aryl group, a lower alkoxy group which is optionally substituted by an aryl group, a lower alkoxy group substituted by an aromatic heterocyclic ring containing N atom(s), R3 is an aryl group, a heterocyclic ring containing N atom(s), a lower alkyl group, a lower alkoxy group, a cyclo lower alkoxy group, a hydroxy group substituted by a heterocyclic ring containing N atom(s), or an amino group (each of which is optionally substituted), and R3 and a substituent in Y may be combined to form a lactone ring. The compound of the present invention has excellent selective PDE V inhibitory activity and therefore, is useful as a therapeutic or prophylactic drug for treating various diseases due to functional disorders on cGMP-signaling.
    • 式(I)的环状化合物或其药理学上可接受的盐,其中X为-CH-或-N-,Y为-NH-,-NR 4 - , - S - , - O-,-CH-N-,-N-CH-,-NN-,-CH-CH-等,R 1是低级烷氧基,氨基,杂环 含有N原子或被含有N原子(各自任选被取代的)的杂环取代的羟基,R 2是低级烷基氨基,其任选被 芳基,任选被芳基取代的低级烷氧基,被含有N原子的芳族杂环取代的低级烷氧基,R 3是芳基,杂环基 含有N原子,低级烷基,低级烷氧基,环低级烷氧基,被含有N原子的杂环取代的羟基或氨基(各自任选被取代) )和R 3和Y中的取代基可以组合形成a 内酯环。 本发明的化合物具有优异的选择性PDE V抑制活性,因此可用作治疗或预防药物,用于治疗由于cGMP信号传导的功能紊乱引起的各种疾病。
    • 6. 发明授权
    • .beta.-carboline derivative
    • β-咔啉衍生物
    • US5434148A
    • 1995-07-18
    • US67931
    • 1993-05-27
    • Koichiro YamadaMasataka HikotaTakeshi YuraToshiro ShikanoMasaaki Nagasaki
    • Koichiro YamadaMasataka HikotaTakeshi YuraToshiro ShikanoMasaaki Nagasaki
    • C07D471/04A61K31/44A61K31/55C07D487/04
    • C07D471/04
    • Disclosed are .beta.-carboline derivatives represented by the formula: ##STR1## wherein R.sup.1 represents hydrogen atom, a lower alkyl group, a lower alkoxy group or hydroxy group; R.sup.5 represents hydrogen atom, or R.sup.1 and R.sup.5 are bonded to represent a lower alkylenedioxy group; R.sup.2 represents hydrogen atom, a halogen atom, a lower alkoxy group or hydroxy group; R.sup.3 represents hydrogen atom, a carbamoyl lower alkyl group, a lower alkyl group, a carboxy lower alkyl group or a lower alkoxycarbonyl lower alkyl group; R.sup.4 represents hydrogen atom, a lower alkyl group, a carboxy lower alkyl group, a lower alkoxycarbonyl lower alkyl group, a lower alkanoyl group, an arylcarbonyl group, a lower alkanesulfonyl group, a lower alkoxycarbonyl group, an aralkyl group, formyl group or a di(lower alkyl)sulfamoyl group; n represents 0, 1 or 2; and the symbol * represents an asymmetric carbon atom,or a pharmaceutically acceptable salt thereof, and a process for preparing the same.
    • 公开了由下式表示的β-咔啉衍生物:其中R 1表示氢原子,低级烷基,低级烷氧基或羟基; R 5表示氢原子,或者R 1和R 5相连,表示低级亚烷基二氧基; R2表示氢原子,卤素原子,低级烷氧基或羟基; R3表示氢原子,氨基甲酰基低级烷基,低级烷基,羧基低级烷基或低级烷氧羰基低级烷基; R4表示氢原子,低级烷基,羧基低级烷基,低级烷氧基羰基低级烷基,低级烷酰基,芳基羰基,低级链烷磺酰基,低级烷氧基羰基,芳烷基,甲酰基或 二(低级烷基)氨磺酰基; n表示0,1或2; 符号*表示不对称碳原子,或其药学上可接受的盐及其制备方法。